Back to team

Fang-Chi (Cheryl) Chang, MS

Research Associate

,

Platform

Fang-Chi completed her Master of Science degree in Biochemistry and Molecular Biology at Johns Hopkins University in Dr. Andrew Holland’s lab, under the supervision of Dr. Peter Yeow. During her graduate studies, Fang-Chi led a project investigating the mechanisms underlying the sensitivity of novel breast cancer cell lines to small molecule inhibition of the PLK4 kinase. Her pioneering findings identified a crucial biomarker that not only exhibits synthetic lethality with PLK4 inhibition but also predicts the sensitivity of other cancer cell lines to this inhibitor.

Additionally, the research demonstrated the potential to sensitize PLK4 inhibitor-resistant cell lines through the introduction of a secondary drug that mimics the sensitivity mechanism. With PLK4 inhibitors currently undergoing clinical trials for AML patients, this research critically informs patient selection and indication expansion as well as highlighting the power ofsynthetic lethality in cancer therapeutics.

Prior to joining the Holland lab, Fang-Chi gained extensive research experience working in multiple academic labs throughout her undergraduate degree. She utilized deep learning algorithms to classify viral sequences into different taxonomic levels, developed and optimized experiments for elucidating the structure of a yeast prion protein, and optimized a high-throughput screening assay for identifying chemical probes that inhibit the target protein-protein interactions.

This diverse research background equipped her with a robust skill set, enabling her to excel in computational biology, structural biology, and assay development. Fang-Chi is now a Research Associate at General Proximity, where she assists the platform and drug discovery teams in generating a novel class of induced-proximity therapeutics. Outside the lab, she enjoys running, reading murder mystery books, and exploring new coffee shops and restaurants.